Tumor Necrosis Factor Inhibitor Drugs Market (By Product: Humira, Enbrel, Remicade, Simponi, Cimzia; By Application: Autoimmune Disease, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Others, By Sales Channel: Hospital pharmacies, Specialty pharmacies, Online pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Tumor Necrosis Factor Inhibitor Drugs Market
5.1. COVID-19 Landscape: Tumor Necrosis Factor Inhibitor Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Tumor Necrosis Factor Inhibitor Drugs Market, By Product
8.1. Tumor Necrosis Factor Inhibitor Drugs Market Revenue and Volume, by Product, 2024-2033
8.1.1 Humira
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Enbrel
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Remicade
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Simponi
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
8.1.5. Cimzia
8.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Tumor Necrosis Factor Inhibitor Drugs Market, By Application
9.1. Tumor Necrosis Factor Inhibitor Drugs Market Revenue and Volume, by Application, 2024-2033
9.1.1. Autoimmune disease
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Psoriasis
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Psoriatic arthritis
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. Crohn’s disease
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Ulcerative Colitis
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
9.1.6. Ankylosing spondylitis
9.1.6.1. Market Revenue and Volume Forecast (2021-2033)
9.1.7. Juvenile idiopathic arthritis
9.1.7.1. Market Revenue and Volume Forecast (2021-2033)
9.1.7. Hidradenitis suppurativa
9.1.7.1. Market Revenue and Volume Forecast (2021-2033)
9.1.7. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Tumor Necrosis Factor Inhibitor Drugs Market, By Sales Channel
10.1. Tumor Necrosis Factor Inhibitor Drugs Market Revenue and Volume, by Sales Channel, 2024-2033
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Specialty Pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Specialty Pharmacies
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Tumor Necrosis Factor Inhibitor Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Sales Channel (2021-2033)
Chapter 12. Company Profiles
12.1. UCB Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson & Johnson
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Amgen Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Abbvie
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample